202 related articles for article (PubMed ID: 35963549)
1. Insights on the antiviral mechanisms of action of the TLR1/2 agonist Pam3CSK4 in hepatitis B virus (HBV)-infected hepatocytes.
Desmares M; Delphin M; Chardès B; Pons C; Riedinger J; Michelet M; Rivoire M; Verrier B; Salvetti A; Lucifora J; Durantel D
Antiviral Res; 2022 Oct; 206():105386. PubMed ID: 35963549
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
[TBL] [Abstract][Full Text] [Related]
3. Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes.
Lucifora J; Bonnin M; Aillot L; Fusil F; Maadadi S; Dimier L; Michelet M; Floriot O; Ollivier A; Rivoire M; Ait-Goughoulte M; Daffis S; Fletcher SP; Salvetti A; Cosset FL; Zoulim F; Durantel D
Sci Rep; 2018 Mar; 8(1):5390. PubMed ID: 29599452
[TBL] [Abstract][Full Text] [Related]
4. Latest developments in the treatment of hepatitis B.
Dandri M; Petersen J
Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
[TBL] [Abstract][Full Text] [Related]
5. [The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B].
Lu FM; Wang J; Chen XM; Jiang JN; Zhang WH; Zhao JM; Ren H; Hou JL; Xia NS
Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):105-110. PubMed ID: 28297795
[TBL] [Abstract][Full Text] [Related]
6. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
Tsuge M; Uchida T; Hiraga N; Kan H; Makokha GN; Abe-Chayama H; Miki D; Imamura M; Ochi H; Hayes CN; Shimozono R; Iwamura T; Narumi H; Suzuki T; Kainoh M; Taniguchi T; Chayama K
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373196
[TBL] [Abstract][Full Text] [Related]
7. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
Wong GLH; Gane E; Lok ASF
J Hepatol; 2022 Jun; 76(6):1249-1262. PubMed ID: 35589248
[TBL] [Abstract][Full Text] [Related]
8. Can we cure hepatitis B virus with novel direct-acting antivirals?
Martinez MG; Villeret F; Testoni B; Zoulim F
Liver Int; 2020 Feb; 40 Suppl 1():27-34. PubMed ID: 32077597
[TBL] [Abstract][Full Text] [Related]
9. Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication.
Wang YX; Niklasch M; Liu T; Wang Y; Shi B; Yuan W; Baumert TF; Yuan Z; Tong S; Nassal M; Wen YM
J Hepatol; 2020 May; 72(5):865-876. PubMed ID: 31863794
[TBL] [Abstract][Full Text] [Related]
10. Inducers of the NF-κB pathways impair hepatitis delta virus replication and strongly decrease progeny infectivity
Michelet M; Alfaiate D; Chardès B; Pons C; Faure-Dupuy S; Engleitner T; Farhat R; Riedl T; Legrand AF; Rad R; Rivoire M; Zoulim F; Heikenwälder M; Salvetti A; Durantel D; Lucifora J
JHEP Rep; 2022 Mar; 4(3):100415. PubMed ID: 35141510
[TBL] [Abstract][Full Text] [Related]
11. Review article: novel therapies for hepatitis B virus cure - advances and perspectives.
Lin CL; Kao JH
Aliment Pharmacol Ther; 2016 Aug; 44(3):213-22. PubMed ID: 27302653
[TBL] [Abstract][Full Text] [Related]
12. Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome.
Wu D; Ning Q
J Infect Dis; 2017 Nov; 216(suppl_8):S771-S777. PubMed ID: 29156046
[TBL] [Abstract][Full Text] [Related]
13. Role of Toll-like receptor 2 in the immune response against hepadnaviral infection.
Zhang X; Ma Z; Liu H; Liu J; Meng Z; Broering R; Yang D; Schlaak JF; Roggendorf M; Lu M
J Hepatol; 2012 Sep; 57(3):522-8. PubMed ID: 22617154
[TBL] [Abstract][Full Text] [Related]
14. New paradigms in hepatitis B management: only diamonds are forever.
Coffin CS; Lee SS
Br Med Bull; 2015; 116():79-91. PubMed ID: 26377741
[TBL] [Abstract][Full Text] [Related]
15. Aiming for cure in HBV and HDV infection.
Petersen J; Thompson AJ; Levrero M
J Hepatol; 2016 Oct; 65(4):835-848. PubMed ID: 27270043
[TBL] [Abstract][Full Text] [Related]
16. Alpha-kinase 1 (ALPK1) agonist DF-006 demonstrates potent efficacy in mouse and primary human hepatocyte (PHH) models of hepatitis B.
Xu C; Fan J; Liu D; Tuerdi A; Chen J; Wei Y; Pan Y; Dang H; Wei X; Yousif AS; Yogaratnam J; Zhou Q; Lichenstein H; Xu T
Hepatology; 2023 Jan; 77(1):275-289. PubMed ID: 35699669
[TBL] [Abstract][Full Text] [Related]
17. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.
Uchida T; Imamura M; Hayes CN; Hiraga N; Kan H; Tsuge M; Abe-Chayama H; Zhang Y; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696237
[TBL] [Abstract][Full Text] [Related]
18. Identification of Retinoic Acid Receptor Agonists as Potent Hepatitis B Virus Inhibitors via a Drug Repurposing Screen.
Li B; Wang Y; Shen F; Wu M; Li Y; Fang Z; Ye J; Wang L; Gao L; Yuan Z; Chen J
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30224536
[TBL] [Abstract][Full Text] [Related]
19. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
20. Influence of Pattern Recognition Receptor Ligands on Induction of Innate Immunity and Control of Hepatitis B Virus Infection.
Asadi-Asadabad S; Sarvnaz H; Amiri MM; Mobini M; Khoshnoodi J; Hojjat-Farsangi M; Jeddi-Tehrani M; Golsaz-Shirazi F; Shokri F
Viral Immunol; 2021 Oct; 34(8):531-541. PubMed ID: 34030480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
